Evidence map›Paper›PMID 36775986›Full record

ReviewJournal of extracellular vesicles2023

Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases.

Guoping Li, Tianji Chen, James Dahlman, Lola Eniola-Adefeso, Ionita C Ghiran, Peter Kurre, Wilbur A Lam, Jennifer K Lang, Eduardo Marbán, Pilar Martín and 19 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of extracellular vesicles, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Extracellular vesicles: Navigating new frontiers in glioblastoma therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. A Nanoparticle-Integrated Complete Manufacturing Pipeline of Chemically Engineered Exosomes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Guoping LiCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Tianji ChenDepartment of Pediatrics, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
James DahlmanDepartment of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, Georgia, USA.
Lola Eniola-AdefesoDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
Ionita C GhiranDepartment of Anesthesia and Pain Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA.
Peter KurreChildren's Hospital of Philadelphia, Comprehensive Bone Marrow Failure Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Wilbur A LamWallace H. Coulter Department of Biomedical Engineering, Department of Pediatrics, Emory School of Medicine, Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA.
Jennifer K LangDepartment of Medicine, Division of Cardiology, Jacobs School of Medicine and Biomedical Sciences, Veterans Affairs Western New York Healthcare System, Buffalo, New York, USA.
Eduardo MarbánSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Pilar MartínCentro Nacional de Investigaciones Cardiovasculares (CNIC), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Stefan MommaInstitute of Neurology (Edinger Institute), University Hospital, Goethe University, Frankfurt am Main, Germany.
Malcolm MoosDivision of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA.
Deborah J NelsonDepartment of Pharmacological and Physiological Sciences, The University of Chicago, Chicago, Illinois, USA.
Robert L RaffaiDepartment of Veterans Affairs, Surgical Service (112G), San Francisco VA Medical Center, San Francisco, California, USA.
Xi RenDepartment of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA.
Joost P G SluijterDepartment of Experimental Cardiology, Circulatory Health Laboratory, Regenerative Medicine Centre, UMC Utrecht, University Utrecht, Utrecht, The Netherlands.
Shannon L StottMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
Gordana Vunjak-NovakovicDepartment of Biomedical Engineering, Department of Medicine, Columbia University, New York, New York, USA.
Nykia D WalkerDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland, USA.
Zhenjia WangDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.
Kenneth W WitwerDepartment of Molecular and Comparative Pathobiology, Department of Neurology and Neurosurgery, and The Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Phillip C YangDivision of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Martha S LundbergDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Margaret J OchocinskaDivision of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Renee WongDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Guofei ZhouDivision of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Stephen Y ChanPittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Saumya DasCardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Prithu SunddPittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Funding

Tissue Engineering Resource Center: TTDP41EB027062 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gordana Vunjak-Novakovic · 2019 to 2026
$12.6M
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failureR35HL150807 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Saumya Das · 2020 to 2026
$6.7M
Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest SyndromeR01HL128297 · NHLBI · VERSITI WISCONSIN, INC. · PI SUNDD, PRITHU · 2015 to 2025
$5.4M
Defining the Complex Biology of the miR-130/301 Family in Pulmonary HypertensionR01HL124021 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHAN, STEPHEN Y · 2014 to 2025
$4.9M
Iron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary HypertensionR01HL122596 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHAN, STEPHEN Y · 2015 to 2024
$4.5M
Next-generation extracellular vesicle biologics to target central nervous system and peripheral reservoirs of HIVR01AI144997 · NIAID · JOHNS HOPKINS UNIVERSITY · PI RAMRATNAM, BHARAT, WITWER, KENNETH W · 2019 to 2023
$4.0M
Exosome-mediated cardioprotection and regenerationR01HL124074 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO · 2014 to 2021
$4.0M
Extracellular Vesicle and Extracellular RNA Biomarkers of HIV-1 Central Nervous System Pathogenesis and Cigarette UseR01DA047807 · NIDA · JOHNS HOPKINS UNIVERSITY · PI WITWER, KENNETH W · 2018 to 2022
$3.7M
Exosome Therapeutics to Dissect HFpEF MechanismsR01HL155346 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO, VAN EYK, JENNIFER E · 2021 to 2024
$3.3M
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell diseaseR01HL141080 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D, NOVELLI, ENRICO M · 2019 to 2022
$3.1M
CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell DiseaseR01HL166345 · NHLBI · VERSITI WISCONSIN, INC. · PI Prithu Sundd · 2023 to 2026
$3.1M
Genetic and hypoxic control of a lncRNA axis orchestrates endothelial reprogramming in pulmonary hypertensionR01HL151228 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Stephen Y Chan · 2023 to 2026
$2.8M
BLRD VA IK2 BX004097NCATS NIH HHS UH3 TR002878NCI NIH HHS R01 CA226871NCI NIH HHS UH3 CA241694NHLBI NIH HHS R01 HL122596NHLBI NIH HHS R01 HL124021NHLBI NIH HHS R01 HL124074NHLBI NIH HHS R01 HL128297NHLBI NIH HHS R01 HL141080NHLBI NIH HHS R01 HL151228NHLBI NIH HHS R01 HL155346NHLBI NIH HHS R01 HL166345NHLBI NIH HHS R35 HL150807NHLBI NIH HHS R56 HL141206NIAID NIH HHS R01 AI144997NIBIB NIH HHS P41 EB027062NIBIB NIH HHS R01 EB027078NIDA NIH HHS R01 DA047807NIMH NIH HHS R33 MH118164
6 · The paper itself

Abstract

Extracellular vesicles (EVs) carry diverse bioactive components including nucleic acids, proteins, lipids and metabolites that play versatile roles in intercellular and interorgan communication. The capability to modulate their stability, tissue-specific targeting and cargo render EVs as promising nanotherapeutics for treating heart, lung, blood and sleep (HLBS) diseases. However, current limitations in large-scale manufacturing of therapeutic-grade EVs, and knowledge gaps in EV biogenesis and heterogeneity pose significant challenges in their clinical application as diagnostics or therapeutics for HLBS diseases. To address these challenges, a strategic workshop with multidisciplinary experts in EV biology and U.S. Food and Drug Administration (USFDA) officials was convened by the National Heart, Lung and Blood Institute. The presentations and discussions were focused on summarizing the current state of science and technology for engineering therapeutic EVs for HLBS diseases, identifying critical knowledge gaps and regulatory challenges and suggesting potential solutions to promulgate translation of therapeutic EVs to the clinic. Benchmarks to meet the critical quality attributes set by the USFDA for other cell-based therapeutics were discussed. Development of novel strategies and approaches for scaling-up EV production and the quality control/quality analysis (QC/QA) of EV-based therapeutics were recognized as the necessary milestones for future investigations.

Indexed as

Extracellular VesiclesNucleic AcidsCell CommunicationLungSleepUnited StatesNucleic Acidsextracellular vesicles (EVs)Heart, lung, blood and sleep (HLBS) diseasestherapeutics and diagnostics

Identifiers

PMID36775986
PMCPMC9923045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.